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Genetic Mapping of Glutaric Aciduria, Type 3,
to Chromosome 7 and Identification
of Mutations in C7orf10
Eric A. Sherman,1 Kevin A. Strauss,2,3,4 Silvia Tortorelli,5 Michael J. Bennett,6 Ina Knerr,7
D. Holmes Morton,2,3,4 and Erik G. Puffenberger2,3,*
While screeningOldOrderAmishchildren for glutaric aciduria type1 (GA1)between1989and1993,we found threehealthychildrenwho
excreted abnormalquantitiesof glutaric acidbut low3-hydroxyglutaric acid, a patternconsistentwithglutaric aciduria type3 (GA3).None
of these children had theGCDH c.1262C/Tmutation that causes GA1 among the Amish. Using single-nucleotide polymorphism (SNP)
genotypes, we identiﬁed a shared homozygous 4.7 Mb region on chromosome 7. This region contained 25 genes including C7orf10, an
open reading framewith a putativemitochondrial targeting sequence and coenzyme-A transferase domain. Direct sequencing ofC7orf10
revealed that the three Amish individuals were homozygous for a nonsynonymous sequence variant (c.895C/T, Arg299Trp). We then
sequenced three non-Amish children with GA3 and discovered two nonsense mutations (c.322C/T, Arg108Ter, and c.424C/T,
Arg142Ter) in addition to the Amishmutation. Two pathogenic alleles were identiﬁed in each of the six patients. There was no consistent
clinical phenotype associated with GA3. In affected individuals, urine molar ratios of glutarate to its derivatives (3-hydroxyglutarate,
glutarylcarnitine, andglutarylglycine)were elevated, suggesting impaired formationof glutaryl-CoA.Theseobservations reﬁneourunder-
standing of the lysine-tryptophan degradation pathway and have important implications for the pathophysiology of GA1.Glutaric aciduria type 1 (GA1) is one of the most common
genetic disorders of the Old Order Amish of Lancaster
County, Pennsylvania. Infants with GA1 have elevations
of glutarate, 3-hydroxyglutarate, and glutarylcarnitine in
blood and urine. Without timely diagnosis and therapy,
GA1 results in striatal degeneration and severe dystonia.1,2
Between 1989 and 1993, we screened 1223 Amish infants
for GA1 by urine organic-acid analysis with gas chromatog-
raphy-mass spectrometry. In the process, we identiﬁed
three healthy children who excreted large quantities of
glutarate but low 3-hydroxyglutarate,1 consistent with
the phenotype of glutaric aciduria type 3 (GA3 [OMIM
231690]), ﬁrst described in 1991.3 These children received
no therapy and remained healthy over more than 15 years
of follow-up.
In their original description of GA3,3 Bennett et al. pos-
tulated that glutaryl-CoA degradation in vivo occurred in
two compartments, mitochondria and peroxisomes, corre-
sponding to the GA1 and GA3 phenotype, respectively.
They showed that ﬁbroblast homogenates from a GA3
patient did not produce hydrogen peroxide in the presence
of labeled glutaryl-coenzyme A (CoA) and took this as evi-
dence of a defective peroxisomal glutaryl-CoA oxidase.
This was a compelling idea; it suggested that neurodegen-
erative consequences of GA1 (in contrast to the benign
phenotype of GA3) were rooted in themitochondrial locus
of the disturbance.
However, no gene encoding a glutaryl-CoA oxidase has
been identiﬁed, and subsequent work showed that,604 The American Journal of Human Genetics 83, 604–609, Novembin vitro, a small amount of glutaryl-CoA is oxidized in per-
oxisomes by an inducible acyl-CoA oxidase (ACOX1, a.k.a.
palmitoyl-CoA oxidase), whereas this enzyme probably
mediates little or no glutaryl-CoA degradation in vivo.4,5
As a further complication, case reports in 1975 described
disabled children with alpha-ketoadipic and alpha-amino-
adipic aciduria who were thought to have a defect in the
oxidative decarboxylation of alpha-ketoadipate to form
glutaryl-CoA.6–8 However, no enzyme mediating this reac-
tion was ever found.
In an effort to clarify the metabolic pathology of the
lysine-tryptophan degradation pathway, we took advan-
tage of the natural occurrence of both GA1 and GA3
among the Pennsylvania Old Order Amish.9 This study
was approved by the Institutional Review Board of Lancas-
ter General Hospital and parents consented in writing to
molecular genetic testing. In addition to the three Old
Order Amish patients, three other GA3 patients were stud-
ied, including an American child ofmixed European ances-
try and two previously described patients, one German10
and one Pakistani.3
Single-nucleotide polymorphism (SNP) genotyping was
performed with the GeneChip Mapping 10K Assay Kit (Af-
fymetrix, Santa Clara, CA, USA) as previously described.11
Data were analyzed inMicrosoft Excel spreadsheets (Micro-
soft Corporation, Redmond, WA, USA) that were custom
formatted at the Clinic for Special Children. SNP positions
came from Affymetrix genome annotation ﬁles, and geno-
type data came from the Affymetrix GeneChip Human1Ephrata High School, Ephrata, PA 17522, USA; 2Clinic for Special Children, Strasburg, PA 17579, USA; 3Biology Department, Franklin and Marshall Col-
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icine and Pathology, Mayo, Clinic School ofMedicine, Rochester, MN 55905, USA; 6Department of Pathology and LaboratoryMedicine, University of Penn-
sylvania and Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA; 7Children’s and Adolescent’s Hospital, University of Erlangen-Nuremberg,
Erlangen 91054, Germany
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Mapping 10K Xba 142 Arrays. Data analyses were designed
for identiﬁcation of genomic regions that were identically
homozygous between all three affected Old Order Amish
individuals. Such analyses assume mutation and locus ho-
mogeneity. Two-point LOD scores were calculated for each
genotyped SNP with an approach similar to Broman and
Weber.12 Cumulative two-point LOD scores for blocks of
homozygous SNPs were considered the location score for
that region, providing a relative measure that the region
harbors the disease gene. Genotype data from 80 healthy
Old Order Amish samples as well as from previous stud-
ies11,13–15 were used for estimation of population-speciﬁc
SNP allele frequencies.
Genome-wide autozygosity mapping using three dis-
tantly related Old Order Amish children with GA3 identi-
ﬁed a homozygous 4.7 Mb region on chromosome 7p14
bounded by SNPs rs4128395 and rs200463 (Figure 1). The
region was queried for candidate genes with both the Uni-
versity of California Santa Cruz (UCSC) and National Cen-
ter for Biotechnology Information (NCBI) genome
browsers. The region contained 25 known or hypothetical
genes. For each gene, we assessed function and expression
to generate a priority list for sequencing. We chose
C7orf10 (OMIM 609187) as a candidate based on its puta-
tive CoA transferase function (NCBI Gene) and mitochon-
drial targeting sequence (MitoProt).
C7orf10 was subjected to polymerase chain reaction
(PCR) ampliﬁcation and sequencing. PCR primers were de-
signed (Primer3) for ampliﬁcationof the coding regions and
adjacent intron-exon boundaries. DNA sequence fromGA3
patients was compared to the human reference sequence
and dbSNP so that potential pathogenic sequence variants
could be identiﬁed. All three Amish GA3 subjects were ho-
mozygous for a nonsynonymous c.895C/T (Arg299Trp)
change in exon 11. This sequence variant is not a known
polymorphism (dbSNP) and is highly conserved in all
species tested. Among 150 Amish control individuals, we
identiﬁed 26 who were heterozygous and one who was
Figure 1. Two Mapping Parameters, the
Number of Consecutive Homozygous
SNPs and the Location Score, Were Max-
imized on Chromosome 7p14.1-p14.2 in
Three Old Order Amish GA3 Patients
The region comprised 19 SNPs and con-
tained 25 known genes including C7orf10.
homozygous for the C7orf10
c.895C/T variant. Retrospectively,
we collected a urine sample from this
c.895C/T homozygote, a healthy
35-year-old man, and conﬁrmed
high glutaric acid excretion (40
mmol/mol creatinine; control 0.9 5
0.5 mmol/mol Cr).
We subsequently analyzed DNA
from three non-Amish GA3 subjects
and identiﬁed C7orf10mutations in all of them (Figure 2).
One patient was heterozygous for the Amish c.895C/T
allele and a secondvariant, c.424C/T (Arg142Ter). The lat-
ter, a nonsense change, is predicted to produce a truncated,
nonfunctional protein. A second child, fromGermany, was
homozygous for the same c.895C/T mutation found in
the Amish patients. Surprisingly, the intragenic SNPs indi-
cated that themutation in this patient residedonadifferent
haplotype (Figure 2). This circumstance could be explained
by an old intragenic recombination or a recurrent muta-
tion; however, the observation that the SNP genotypes
were identical in patients 1 and 5 at the 30 end of C7orf10
(and beyond) lends support to the hypothesis of intragenic
recombination. Finally, sequence analysis of the Pakistani
child originally described by Bennett et al.3 revealed homo-
zygosity for c.322C/T (Arg108Ter). This exon 4 nonsense
mutation is predicted to result in a nonfunctional protein.
Urine organic acids were measured by gas chromatogra-
phy-mass spectrometry.16 Glutarylglycine and glutarylcar-
nitine were measured with electrospray-ionization tandem
mass spectrometry.16,17 To quantitate 3-hydroxyglutarate
and glutarylglycine levels, we added labeled 3-hydroxyglu-
taric acid and 13C2-glutarylglycine, respectively, as internal
standards. For biochemical comparisons, we used urine
samples from six Amish GA3 patients and 19 Amish GA1
patients (GCDH c.1262C/T homozygotes), ages 1 week to
16 years, as well as 13 healthy Amish siblings and parents
of GA3 subjects (designated controls). Urine metabolite
values for three groups (control, GA3, and GA1) were
studied with one-way analysis of variance (ANOVA). For
ANOVA p values < 0.05, we used Tukey’s posttest to make
pairwise comparisons among groups. We log transformed
urine-metabolite-concentration ratios to produce normal
distributions for ANOVA testing.
Amish GA3 patients had high glutarate excretion
(78.5 5 97 mmol/mol Cr; control 0.9 5 0.5 mmol/mol
Cr) relative to controls (Table 1). Urine glutarate levels
were not distinguishable between GA1 and GA3 subjects;The American Journal of Human Genetics 83, 604–609, November 7, 2008 605
Figure 2. Single-Nucleotide Polymorphism and C7orf10 Mutation Table for Six GA3 Patients
SNP genotypes were derived from Affymetrix 10K GeneChips and direct sequencing of C7orf10; SNP physical locations were from human
genome build 36. The red box delimits the C7orf10 locus, and the gray highlighting indicates homozygous genotype blocks in each
patient.glutarate excretion was highly variable within these groups
(i.e., across three orders of magnitude) and overlapped
broadly between them. In contrast, individuals with GA3
had normal urinary 3-hydroxyglutarate, glutarylcarnitine,
and glutarylglycine values, whereas GA1 patients had ele-
vations of all three derivatives, particularly 3-hydroxyglu-
tarate. Urine acetylcarnitine levels were also high in GA1
patients (455.8 5 602.4 mmol/mol Cr; control 0.3 5 0.3
mmol/mol Cr), possibly reﬂecting L-carnitine supplemen-
Table 1. Urine Metabolites as Mean and Standard Deviation
for GA3, GA1, and Healthy Control Subjects
Metabolites
(mmol/mol Cr)
Controls
(n ¼ 13)
GA3
(n ¼ 6)
GA1
(n ¼ 19)
ANOVA
p value
Glutarate 0.93
(0.53)
78.50
(97.00)
288.60
(428.60)a
0.039
3-hydroxyglutarate 1.37
(1.06)
3.97
(0.83)
161.20
(118.30)a,b
<0.0001
Glutarylcarnitine 0.03
(0.02)
0.05
(0.06)
18.65
(16.06)a,b
<0.0001
Acetylcarnitine 0.25
(0.27)
0.58
(0.62)
455.80
(602.40)a
0.001
Glutarylglycine 0.37
(0.11)
0.39
(0.13)
1.90
(1.37)a,b
0.0002
Metabolite Ratios (mol:mol)c
Glutarylcarnitine/
total acylcarnitines
0.03
(0.01)
0.03
(0.01)
0.25
(0.39)a,b
0.0002
Glutarate/
3-hydroxyglutarate
0.57
(0.37)
18.75
(20.61)a
1.72
(2.07)b
<0.0001
Glutarate/
glutarylcarnitine
38.5
(29.0)
1784.0
(920.0)a
95.3
(265.3)b
<0.0001
a Different from control (Tukey, p < 0.05).
b Different from GA3 (Tukey, p < 0.05).
c Log transformed for ANOVA test.606 The American Journal of Human Genetics 83, 604–609, Novembtation.18 Compared to both control and GA1 subjects,
molar ratios of glutarate to 3-hydroxyglutarate and gluta-
rylcarnitine were markedly elevated in GA3 (Figure 3), sug-
gesting that the loss of C7orf10 function interferes with the
formation of glutarate derivatives through a glutaryl-CoA
intermediate (Figure 4).
In striking contrast to GA1, individuals with GA3 have
no consistent disease phenotype. This fact, together with
urinemetabolite data, provides some insight into the path-
ophysiology of GA1. Relative to individuals with GA1,
those with GA3 produce comparatively little 3-hydroxy-
glutarate, glutarylcarnitine, or glutarylglycine; in GA3 the
ratios of glutarate to these metabolites are 10- to 20-fold
higher than they are in GA1 (Table 1 and Figure 3). This
suggests that individuals with GA3 produce little or no
glutaryl-CoA because this compound is the predicted pre-
cursor of glutarylcarnitine, glutarylglycine, and 3-hydrox-
yglutarate in tissues (Figure 4). Such a ﬁnding shows that
glutaryl-CoA or one of its downstream derivatives is likely
to be the primary neurotoxin in GA1, an idea consistent
with recent in vitro work.19
We identiﬁed four different mutations in C7orf10 that
cause GA3. One of these, c.895C/T, underlies the Amish
form of the condition. There is no existing functional data
on the C7orf10 protein, but analysis of its amino acid se-
quence suggests that it functions in mitochondria rather
than peroxisomes (MitoProt) and that one of its actions
might be to transfer CoA to glutarate (NCBI Gene). On
the basis of these ﬁndings, we postulate that alpha-ketoa-
dipic aciduria, GA3, and GA1 arise from sequential defects
along a common mitochondrial lysine-tryptophan degra-
dation pathway. Within this pathway, C7orf10 may act
independently or as part of a multiunit complex (Figure 4).
Future studies to ascertain the exact enzymatic functioner 7, 2008
and cellular localization of the C7orf10 gene product are
critical to advance our knowledge of this metabolic
pathway.
The incidence of GA3 in the general population is
unknown. Because these individuals do not produce
abnormal quantities of glutarylcarnitine, they are not de-
tected by newborn screening methods based on tandem
mass spectrometry analysis of blood spots on dried ﬁlter
paper. However, clinical laboratories commonly encounter
isolated elevations of urine glutaric acid during routine or-
ganic-acid analysis and, because GA3 does not appear to
Figure 3. Urine Metabolite Quantitation in Patients with GA1
and GA3 and Normal Controls
Individuals with GA3 (black triangles) and GA1 (white circles) have
elevated urine glutarate relative to controls (gray squares). How-
ever, compared to subjects with GA1, those with GA3 have much
lower levels of glutarate derivatives: 3-hydroxyglutarate (upper
panel), glutarylcarnitine (middle panel), and glutarylglycine
(lower panel). Note that all axes are in log 10 scale.The Americancause disease, the incidence is certainly underestimated.
Our ﬁndings provide a rationale for sequencing C7orf10
in individuals with isolated, persistent, and unexplained
glutaric aciduria. Perhaps more importantly, however, the
present study brings the pathophysiology of GA1 into
sharper focus. Future in vitro and in vivo studies of GA1
should concentrate on elucidating precisely how the intra-
mitochondrial formation of glutaryl-CoA interferes with
the metabolism and survival of striatal neurons.
In conclusion,we used 10,000marker SNPmicroarrays to
genetically map GA3 to chromosome 7p14 and demon-
strated that the disorder is caused by mutations in
C7orf10. On the basis of our ﬁndings, we postulate that
alpha-ketoadipic aciduria,GA3, andGA1arise fromsequen-
tial molecular lesions along a common mitochondrial
lysine-tryptophan degradation pathway. Consistent with
recent in vitro studies,19 our results suggest that the forma-
tion of glutaryl-CoA in mitochondria is an integral part of
the histotoxic process in GA1.
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